nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Tasosartan—AGTR2—stomach cancer	0.0549	0.771	CrCbGaD
Azilsartan medoxomil—AGTR1—blood vessel—stomach cancer	0.0472	0.274	CbGeAlD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—AGTR2—stomach cancer	0.0275	0.0597	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—hematopoietic system—stomach cancer	0.0251	0.146	CbGeAlD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—ACE—stomach cancer	0.0234	0.051	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—epithelium—stomach cancer	0.023	0.133	CbGeAlD
Azilsartan medoxomil—AGTR1—smooth muscle tissue—stomach cancer	0.0221	0.128	CbGeAlD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ITGA5—stomach cancer	0.0193	0.0421	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ITGA8—stomach cancer	0.0187	0.0406	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ITGA5—stomach cancer	0.0184	0.04	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—lymphoid tissue—stomach cancer	0.0177	0.103	CbGeAlD
Azilsartan medoxomil—AGTR1—endocrine gland—stomach cancer	0.0144	0.0837	CbGeAlD
Azilsartan medoxomil—AGTR1—liver—stomach cancer	0.013	0.0755	CbGeAlD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—ADRB2—stomach cancer	0.0112	0.0244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—ACE Inhibitor Pathway—NOS3—stomach cancer	0.0109	0.0237	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Floxuridine—stomach cancer	0.0109	0.0367	CcSEcCtD
Azilsartan medoxomil—AGTR1—lymph node—stomach cancer	0.00999	0.0579	CbGeAlD
Azilsartan medoxomil—Telmisartan—PPARG—stomach cancer	0.00976	0.137	CrCbGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—KISS1R—stomach cancer	0.0096	0.0209	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—KISS1R—stomach cancer	0.00948	0.0206	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Floxuridine—stomach cancer	0.00906	0.0306	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—ADRB2—stomach cancer	0.00888	0.0193	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.00859	0.0187	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide GPCRs—AGTR2—stomach cancer	0.00846	0.0184	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—MET—stomach cancer	0.00783	0.017	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FYN—stomach cancer	0.0073	0.0159	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Floxuridine—stomach cancer	0.00663	0.0224	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.00636	0.0138	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Floxuridine—stomach cancer	0.00632	0.0213	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mitomycin—stomach cancer	0.00625	0.0211	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—KISS1—stomach cancer	0.00619	0.0135	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—KISS1—stomach cancer	0.00611	0.0133	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Irinotecan—stomach cancer	0.006	0.0202	CcSEcCtD
Azilsartan medoxomil—Rash—Floxuridine—stomach cancer	0.00583	0.0197	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Floxuridine—stomach cancer	0.00582	0.0196	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.00553	0.012	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Floxuridine—stomach cancer	0.00549	0.0185	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CDH1—stomach cancer	0.00536	0.0117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—RGS2—stomach cancer	0.00532	0.0116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GAST—stomach cancer	0.00532	0.0116	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Mitomycin—stomach cancer	0.0052	0.0176	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—stomach cancer	0.00518	0.0113	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Mitomycin—stomach cancer	0.00496	0.0167	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—stomach cancer	0.00491	0.0107	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—KISS1R—stomach cancer	0.00484	0.0105	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Mitomycin—stomach cancer	0.0048	0.0162	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.00476	0.0104	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.00476	0.0104	CbGpPWpGaD
Azilsartan medoxomil—Hyperuricaemia—Methotrexate—stomach cancer	0.00474	0.016	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—stomach cancer	0.00466	0.0654	CrCbGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—stomach cancer	0.0046	0.01	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.0046	0.01	CbGpPWpGaD
Azilsartan medoxomil—Rash—Mitomycin—stomach cancer	0.00457	0.0154	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Mitomycin—stomach cancer	0.00457	0.0154	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Methotrexate—stomach cancer	0.00448	0.0151	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Epirubicin—stomach cancer	0.00444	0.015	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Irinotecan—stomach cancer	0.00436	0.0147	CcSEcCtD
Azilsartan medoxomil—Nausea—Mitomycin—stomach cancer	0.00431	0.0145	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Epirubicin—stomach cancer	0.00419	0.0141	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—stomach cancer	0.00411	0.0138	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.0041	0.00891	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Irinotecan—stomach cancer	0.00402	0.0136	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Capecitabine—stomach cancer	0.00402	0.0136	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—F2R—stomach cancer	0.00399	0.00867	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—AGTR2—stomach cancer	0.00398	0.00866	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—stomach cancer	0.00397	0.00863	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—F2R—stomach cancer	0.00394	0.00856	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—stomach cancer	0.00388	0.0131	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—ANXA1—stomach cancer	0.00375	0.00815	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Irinotecan—stomach cancer	0.00371	0.0125	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—ANXA1—stomach cancer	0.0037	0.00805	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—stomach cancer	0.00368	0.008	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK8—stomach cancer	0.00359	0.00781	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP8—stomach cancer	0.00358	0.00779	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.00357	0.00776	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HRH4—stomach cancer	0.0035	0.00761	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.00335	0.00729	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK3—stomach cancer	0.00314	0.00682	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—KISS1—stomach cancer	0.00312	0.00679	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—stomach cancer	0.00312	0.00678	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Irinotecan—stomach cancer	0.00309	0.0104	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—F2R—stomach cancer	0.00308	0.0067	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—stomach cancer	0.00302	0.0102	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—stomach cancer	0.00301	0.0102	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—HTR1A—stomach cancer	0.003	0.00653	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK1—stomach cancer	0.00298	0.00649	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Fluorouracil—stomach cancer	0.00296	0.00998	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Capecitabine—stomach cancer	0.00292	0.00986	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Capecitabine—stomach cancer	0.00292	0.00983	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.00285	0.0062	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—stomach cancer	0.00284	0.00618	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—stomach cancer	0.00283	0.00616	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB1—stomach cancer	0.00281	0.0061	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—stomach cancer	0.0028	0.00944	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—stomach cancer	0.00278	0.00938	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—KISS1R—stomach cancer	0.00274	0.00595	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Irinotecan—stomach cancer	0.00272	0.00917	CcSEcCtD
Azilsartan medoxomil—Fatigue—Irinotecan—stomach cancer	0.00272	0.00916	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL1B—stomach cancer	0.00271	0.00591	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Capecitabine—stomach cancer	0.00269	0.00908	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00267	0.00581	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00264	0.00574	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.0026	0.00878	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—stomach cancer	0.00259	0.00874	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—stomach cancer	0.00259	0.00563	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.00257	0.00559	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Docetaxel—stomach cancer	0.00256	0.00865	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KISS1R—stomach cancer	0.00248	0.00541	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Capecitabine—stomach cancer	0.00248	0.00838	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00248	0.0054	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.0024	0.00523	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—stomach cancer	0.0023	0.005	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—stomach cancer	0.00227	0.00495	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Irinotecan—stomach cancer	0.00226	0.00762	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.00226	0.00761	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.00218	0.00737	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Irinotecan—stomach cancer	0.00215	0.00727	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—stomach cancer	0.00214	0.0072	CcSEcCtD
Azilsartan medoxomil—Pruritus—Fluorouracil—stomach cancer	0.00213	0.0072	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Docetaxel—stomach cancer	0.00211	0.00713	CcSEcCtD
Azilsartan medoxomil—Dizziness—Irinotecan—stomach cancer	0.00208	0.00703	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Capecitabine—stomach cancer	0.00207	0.00697	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Fluorouracil—stomach cancer	0.00206	0.00696	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Capecitabine—stomach cancer	0.00205	0.00691	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—stomach cancer	0.00204	0.00687	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—AGTR2—stomach cancer	0.00203	0.00442	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—stomach cancer	0.00203	0.00685	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—F2R—stomach cancer	0.00201	0.00437	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Methotrexate—stomach cancer	0.002	0.00676	CcSEcCtD
Azilsartan medoxomil—Dizziness—Fluorouracil—stomach cancer	0.00199	0.00673	CcSEcCtD
Azilsartan medoxomil—Rash—Irinotecan—stomach cancer	0.00199	0.0067	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Irinotecan—stomach cancer	0.00198	0.00669	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HRH4—stomach cancer	0.00198	0.0043	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TNF—stomach cancer	0.00197	0.00429	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—HTR1A—stomach cancer	0.00196	0.00426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.00195	0.00424	CbGpPWpGaD
Azilsartan medoxomil—Losartan—ALB—stomach cancer	0.00191	0.0268	CrCbGaD
Azilsartan medoxomil—Rash—Fluorouracil—stomach cancer	0.0019	0.00642	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Fluorouracil—stomach cancer	0.0019	0.00641	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ANXA1—stomach cancer	0.00189	0.00411	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—stomach cancer	0.00188	0.00636	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—stomach cancer	0.00188	0.00634	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—stomach cancer	0.00188	0.00634	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—stomach cancer	0.00188	0.00633	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—stomach cancer	0.00188	0.00633	CcSEcCtD
Azilsartan medoxomil—Nausea—Irinotecan—stomach cancer	0.00187	0.00631	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRB1—stomach cancer	0.00183	0.00398	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Capecitabine—stomach cancer	0.00182	0.00614	CcSEcCtD
Azilsartan medoxomil—Fatigue—Capecitabine—stomach cancer	0.00182	0.00613	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRH4—stomach cancer	0.0018	0.00391	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.0018	0.00391	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Fluorouracil—stomach cancer	0.00179	0.00604	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—KISS1—stomach cancer	0.00176	0.00384	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Doxorubicin—stomach cancer	0.00174	0.00585	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Epirubicin—stomach cancer	0.00173	0.00584	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.00163	0.00548	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.0016	0.00349	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KISS1—stomach cancer	0.0016	0.00348	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—stomach cancer	0.0016	0.0054	CcSEcCtD
Azilsartan medoxomil—Asthenia—Docetaxel—stomach cancer	0.00156	0.00527	CcSEcCtD
Azilsartan medoxomil—Pruritus—Docetaxel—stomach cancer	0.00154	0.0052	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Methotrexate—stomach cancer	0.00154	0.00519	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Methotrexate—stomach cancer	0.00152	0.00514	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.00152	0.00513	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GAST—stomach cancer	0.00152	0.0033	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RGS2—stomach cancer	0.00152	0.0033	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Capecitabine—stomach cancer	0.00151	0.0051	CcSEcCtD
Azilsartan medoxomil—Pruritus—Capecitabine—stomach cancer	0.00149	0.00503	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Docetaxel—stomach cancer	0.00149	0.00502	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRB2—stomach cancer	0.00148	0.00323	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KISS1R—stomach cancer	0.00147	0.00319	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GLI3—stomach cancer	0.00147	0.00319	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Capecitabine—stomach cancer	0.00144	0.00486	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—stomach cancer	0.00144	0.00486	CcSEcCtD
Azilsartan medoxomil—Dizziness—Docetaxel—stomach cancer	0.00144	0.00486	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Epirubicin—stomach cancer	0.00143	0.00481	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.00141	0.00475	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—stomach cancer	0.0014	0.00305	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RBP1—stomach cancer	0.0014	0.00305	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Capecitabine—stomach cancer	0.00139	0.0047	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RGS2—stomach cancer	0.00138	0.003	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GAST—stomach cancer	0.00138	0.003	CbGpPWpGaD
Azilsartan medoxomil—Rash—Docetaxel—stomach cancer	0.00137	0.00463	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—stomach cancer	0.00137	0.00463	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Methotrexate—stomach cancer	0.00135	0.00457	CcSEcCtD
Azilsartan medoxomil—Fatigue—Methotrexate—stomach cancer	0.00135	0.00456	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—stomach cancer	0.00133	0.00449	CcSEcCtD
Azilsartan medoxomil—Rash—Capecitabine—stomach cancer	0.00133	0.00448	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Capecitabine—stomach cancer	0.00133	0.00448	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—stomach cancer	0.00132	0.00445	CcSEcCtD
Azilsartan medoxomil—Nausea—Docetaxel—stomach cancer	0.00129	0.00436	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—stomach cancer	0.00127	0.00428	CcSEcCtD
Azilsartan medoxomil—Fatigue—Epirubicin—stomach cancer	0.00127	0.00427	CcSEcCtD
Azilsartan medoxomil—Nausea—Capecitabine—stomach cancer	0.00125	0.00422	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.00117	0.00396	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—stomach cancer	0.00117	0.00395	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AGTR2—stomach cancer	0.00115	0.0025	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WWOX—stomach cancer	0.00114	0.00248	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—F2R—stomach cancer	0.00114	0.00247	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Methotrexate—stomach cancer	0.00113	0.0038	CcSEcCtD
Azilsartan medoxomil—Pruritus—Methotrexate—stomach cancer	0.00111	0.00374	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—HTR1A—stomach cancer	0.00111	0.00241	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Methotrexate—stomach cancer	0.00107	0.00362	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ANXA1—stomach cancer	0.00107	0.00232	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WIF1—stomach cancer	0.00106	0.00231	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRH4—stomach cancer	0.00106	0.00231	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Epirubicin—stomach cancer	0.00105	0.00355	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AGTR2—stomach cancer	0.00104	0.00227	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Epirubicin—stomach cancer	0.00104	0.0035	CcSEcCtD
Azilsartan medoxomil—Dizziness—Methotrexate—stomach cancer	0.00104	0.0035	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRB1—stomach cancer	0.00103	0.00225	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—F2R—stomach cancer	0.00103	0.00224	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Epirubicin—stomach cancer	0.001	0.00339	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HTR1A—stomach cancer	0.001	0.00218	CbGpPWpGaD
Azilsartan medoxomil—Rash—Methotrexate—stomach cancer	0.000989	0.00334	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Methotrexate—stomach cancer	0.000988	0.00333	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKAB1—stomach cancer	0.000979	0.00213	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	0.000976	0.00212	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Doxorubicin—stomach cancer	0.000975	0.00329	CcSEcCtD
Azilsartan medoxomil—Dizziness—Epirubicin—stomach cancer	0.000971	0.00328	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ANXA1—stomach cancer	0.00097	0.00211	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Doxorubicin—stomach cancer	0.000961	0.00324	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KISS1—stomach cancer	0.000946	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RNF43—stomach cancer	0.000946	0.00206	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.000941	0.00205	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRB1—stomach cancer	0.000939	0.00204	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Methotrexate—stomach cancer	0.000932	0.00314	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—stomach cancer	0.00093	0.00314	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	0.000929	0.00202	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	0.000929	0.00202	CbGpPWpGaD
Azilsartan medoxomil—Rash—Epirubicin—stomach cancer	0.000926	0.00312	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—stomach cancer	0.000925	0.00312	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—stomach cancer	0.000901	0.00196	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Doxorubicin—stomach cancer	0.000898	0.00303	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	0.000877	0.00191	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Epirubicin—stomach cancer	0.000872	0.00294	CcSEcCtD
Azilsartan medoxomil—Rash—Doxorubicin—stomach cancer	0.000857	0.00289	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—stomach cancer	0.000856	0.00289	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FST—stomach cancer	0.000843	0.00183	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRB2—stomach cancer	0.000838	0.00182	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HBEGF—stomach cancer	0.000825	0.00179	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RGS2—stomach cancer	0.000813	0.00177	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GAST—stomach cancer	0.000813	0.00177	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Doxorubicin—stomach cancer	0.000807	0.00272	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	0.000806	0.00175	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGG—stomach cancer	0.000771	0.00168	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRB2—stomach cancer	0.000761	0.00166	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PPP2R1A—stomach cancer	0.000746	0.00162	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	0.000746	0.00162	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKAA1—stomach cancer	0.000742	0.00161	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RBP4—stomach cancer	0.000717	0.00156	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—stomach cancer	0.000716	0.00156	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	0.000714	0.00155	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AGTR2—stomach cancer	0.000616	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSPB1—stomach cancer	0.000616	0.00134	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—F2R—stomach cancer	0.000609	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BMP2—stomach cancer	0.000609	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKR1C3—stomach cancer	0.0006	0.0013	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HTR1A—stomach cancer	0.000593	0.00129	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCB—stomach cancer	0.000575	0.00125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ANXA1—stomach cancer	0.000573	0.00125	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRB1—stomach cancer	0.000555	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RPS6—stomach cancer	0.00053	0.00115	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCB—stomach cancer	0.000522	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6ST—stomach cancer	0.00052	0.00113	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HBEGF—stomach cancer	0.000487	0.00106	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6R—stomach cancer	0.000464	0.00101	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RHOA—stomach cancer	0.000461	0.001	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRB2—stomach cancer	0.00045	0.000978	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPP2R1A—stomach cancer	0.000441	0.000959	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RHOA—stomach cancer	0.000419	0.000911	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SMAD4—stomach cancer	0.000409	0.00089	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—stomach cancer	0.000405	0.000881	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FYN—stomach cancer	0.000388	0.000845	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—stomach cancer	0.000368	0.0008	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR2—stomach cancer	0.000365	0.000793	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS2—stomach cancer	0.000334	0.000726	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CAV1—stomach cancer	0.000324	0.000704	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APOA1—stomach cancer	0.000323	0.000703	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCB—stomach cancer	0.000308	0.00067	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6ST—stomach cancer	0.000307	0.000668	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APC—stomach cancer	0.000295	0.000642	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK3—stomach cancer	0.000282	0.000614	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6R—stomach cancer	0.000274	0.000596	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAPK1—stomach cancer	0.000269	0.000585	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—stomach cancer	0.000269	0.000585	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—stomach cancer	0.000257	0.000559	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—stomach cancer	0.000256	0.000558	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—stomach cancer	0.000254	0.000552	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RHOA—stomach cancer	0.000247	0.000538	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—stomach cancer	0.000245	0.000533	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—stomach cancer	0.000233	0.000507	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB2—stomach cancer	0.000229	0.000498	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—stomach cancer	0.000217	0.000472	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—HRAS—stomach cancer	0.000216	0.000469	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1B—stomach cancer	0.000212	0.000461	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—stomach cancer	0.000207	0.000449	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—stomach cancer	0.000202	0.00044	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUN—stomach cancer	0.000202	0.000439	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—stomach cancer	0.000196	0.000427	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—stomach cancer	0.000196	0.000426	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK8—stomach cancer	0.000191	0.000416	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—stomach cancer	0.000176	0.000384	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—stomach cancer	0.000175	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK3—stomach cancer	0.000167	0.000363	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—stomach cancer	0.000162	0.000353	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAPK1—stomach cancer	0.000159	0.000345	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—stomach cancer	0.000159	0.000345	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—stomach cancer	0.00015	0.000326	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—stomach cancer	0.000138	0.0003	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—stomach cancer	0.000133	0.00029	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HRAS—stomach cancer	0.000127	0.000277	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—stomach cancer	0.000122	0.000265	CbGpPWpGaD
